GlassScriptPhysician profile
Sailatha P Thomas
NPI 1447285978
$466.03
in general payments reported to CMS, 2019-2025
13 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.22 · 2022: $96.26 · 2023: $48.65 · 2024: $77.72 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $90.49 | 2025 | Isturisa |
| Amgen INC. | $85.16 | 2025 | Tepezza, Repatha, Evenity |
| Novo Nordisk INC | $59.31 | 2021-2022 | |
| Astellas Pharma US INC | $52.93 | 2023-2024 | Veozah |
| Medtronic, INC. | $32.96 | 2022 | |
| Nevro Corp. | $24.63 | 2023 | Senza |
| Dexcom, INC. | $20.15 | 2024 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $19.67 | 2022 | |
| Mannkind Corporation | $17.91 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.54 | 2022 | |
| Corcept Therapeutics | $16.62 | 2025 | Korlym |
| Intra-Sana Laboratories | $15.31 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Currax Pharmaceuticals LLC | $13.35 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sailatha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.